Table 4 Cardiovascular maces and bleeding
Endpoints | Eptifibatide + ticagrelor | Ticagrelor | P value |
|---|---|---|---|
(n = 152) | (n = 152) | ||
In-hospital MACEs | |||
All-cause mortality | 0 (0%) | 1 (0.66%) | 0.317 |
MI (types 1 and 4) | 9 (5.92%) | 20 (13.15%) | 0.032* |
TVR | 1 (0.66%) | 3 (1.97%) | 0.314 |
Stent thrombosis | 1 (0.66%) | 0 (0%) | 0.317 |
Stroke/TIA | 1 (0.66%) | 2 (1.31%) | 0.562 |
Overall MACEs | 12 (7.89%) | 26 (17.12%) | 0.015* |
12-month MACEs | |||
All-cause mortality | 2 (1.31%) | 2 (1.31%) | 1 |
MI (types 1 and 4) | 15 (9.87%) | 28 (18.42%) | 0.032* |
TVR | 5 (3.29%) | 6 (3.94%) | 0.759 |
Stent thrombosis | 1 (0.66%) | 0 (0%) | 0.317 |
Stroke/TIA | 3 (1.97%) | 2 (1.31%) | 0.652 |
Overall MACEs | 26 (17.11%) | 38 (25%) | 0.091 |
In-hospital bleeding | |||
Major bleeding | 1 (0.66%) | 1 (0.66%) | 1 |
Minor bleeding | 29 (19.08%) | 26 (17.11%) | 0.655 |
Any bleeding | 30 (19.74%) | 27 (17.76%) | 0.659 |
12-month bleeding | |||
Major bleeding | 4 (2.63%) | 3 (1.97%) | 0.702 |
Minor bleeding | 38 (25%) | 35 (23.02%) | 0.687 |
Any bleeding | 42 (27.63%) | 38 (25%) | 0.602 |